Blood test and
MRI combination in prostate cancer screening can reduce overdiagnosis, societal
costs
The
combination of a novel blood test and magnetic resonance imaging (MRI) can
reduce overdiagnosis of low-risk cancers as well as societal costs in prostate
cancer screening, according to a cost-effectiveness study from Karolinska
Institutet published in the journal European Urology.
No comments:
Post a Comment